Antitumor Activity of -y-Interferon in Ascitic and Solid Tumor Models of Human Ovarian Cancer

Cancer Research

Volumn 51, Issue 24, 1991, Pages 6643-6649

  Malik, Saleem T A ^a,b,c   Knowles, Richard G ^a,b,c   East, Nick ^a,b,c   Lando, Danielle ^a,b,c   Stamp, Gordon ^a,b,c   Balkwill, Frances R ^a,b,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR;

ANIMAL; ASCITES; CYSTADENOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA, RECOMBINANT; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TRYPTOPHAN;

EID: 0026337879     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Silverberg, E., Boring, C. C., and Squires, T. S. Cancer statistics 1990. Ca-Cancer J. Clin., 40: 9-26, 1990.
2. Bargmann, F. Carcinoma of the ovary, a clinicopathological study of 86 autopsied cases with special reference to the mode of spread. Acta Gynecol. Scand., 5:211-221, 1966.
3. Tobias, J. S., and GrifHths, C. T. Management of ovarian carcinoma. N. Engl. J. Med., 294:877-882, 1976.
4. Oozols, R., Garvin, A. J., and Costa, J. Advanced ovarian cancers: correlation of histologic grade with response to therapy and survival. Cancer (Phila.), 45: 572-581, 1980.
5. Berek, J. S. Intraperitoneal adoptive immunotherapy for peritoneal cancer. J. Clin. Oncol., 8:1610-1612,1991.
6. Rath, U., Kaufmann, M., Schmid, H., Hofmann, J., Wiedenmann, B., Kist, A., Kempeni, J., Schlick, E., Bastert, G., Kommerell, B., and Mannel, D. Effect of intraperitoneal recombinant human tumor necrosis factor a on malignant ascites. Eur. J. Cancer, 27: 121-125,1991.
7. Rambaldi, A., Introna, M., Colotta, F.,Landolfo, S., Colombo, N., Mangioni, C., and Mantovani, A. Intraperitoneal administration of interferon beta in ovarian cancer patients. Cancer (Phila.), 56:294-301,1985.
8. Stewart, J. A., Belinson, J. L., Moore, A. L., Ctorighi, J. A., Grant, B. W. Haugh, L. D., Roberts, J. D., Albertini, R. J., and Brandan, R. F. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res., 50: 6302-6310, 1990.
9. Steis, R. G., Urba, W. J., VanderMolen, L. A., Bookman, M. A., Smith II, J. W., Clark, J. W., Miller, R. L., Crum, E. D., Beckner, S. K., McKnight, J. E., Ozols, R. F., Stevenson, H. C., Young, R. C., and Longo, D. L. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. Clin. Oncol., 8: 1618-1629, 1990.
10. Welander, C. E. Interferon in the treatment of ovarian cancer. Semin. Oncol., 15 (Suppl. 5); 26-29, 1988.
11. Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., Brady, J., Greene, T., Ettinger, L. M., Lagasse, L. D., Bonnem, E. M., Spiegel, R. J., and Zighelboim, J. Intraperitoneal recombinant a-interferon for salvage immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res., 45:4447-4453, 1985.
12. Willemse, P. H. B., De Vries, E. G. E., Mulder, N. H., Aalders, J. G., Bouma, J., and Sleijfer, D. T. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur. J. Cancer, 26: 353-358, 1990.
13. Allavena, P., Peccatori, F., Maggioni, D., Erroi, A., Sironi, M., Colombo, N., Lissoni, A., Galazka, A., Meiers, W., Mangioni, C., and Mantovani, A. Intraperitoneal recombinant 7-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res., 50: 7318-7323, 1990.
14. D'Acquisto, R., Markman, M., Hakes, T., Rubin, S., Hoskins, W., and Lewis, J. L. A phase I trial of intraperitoneal recombinant 7-interferon in advanced ovarian carcinoma. J. Clin. Oncol., 6:689-695, 1988.
15. Welander, C. E., Homesley, H. D., Reich, S. D., and Levin, E. A. A phase II study of the efficacy of recombinant interferon 7 in relapsing ovarian adenocarcinoma. Am. J. Clin. Oncol., II: 465-469, 1988.
16. Pujade-Lauraine, E., Guastella, J. P., Colombo, N., Namer, N., Fumoleau, P., Monnier, A., Nooy, M. A., Falkson, G., Mignot, L., Bugat, R., Oliveira, C. M. D., Mousseau, M., Netter, G., Oberiing, F., CoifTier, B., and Brandely, M. Intraperitoneal human r-IFN 7 as treatment of residual carcinoma (OC) and laparotomy (SLL). Proc. Am. Soc. Clin. Oncol., 10: 195, 1991.
17. Malik, S. T. A., Griffin, D. B., Fiers, W., and Balkwill, F. R. Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int. J. Cancer., I: 918-925, 1989.
18. Naylor, M. S., Malik, S. T. A., Stamp, G. W. H., Jobling, T., and Balkwill, F. R. In situ detection of tumor necrosis factor in human ovarian cancer specimens. Eur. J. Cancer, 26: 1027-1030,1990.
19. Malik, S. T. A., Naylor, M. S., East, N., OlifT, A., and Balkwill, F. R. Cells secreting tumor necrosis factor show enhanced metastasis in nude mice. Eur. J. Cancer, 26: 1031-1034,1990.
20. Friereich, E. J., Gehan, R. A., Rail, D. A., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep., 50: 219-244, 1966.
21. Takikawa, O., Kuroiwa, T., Yamazaki, F., and Kido, R. Mechanism of interferon action-characterization of indoleamine 2,3-dioxygenase induction in cultured human cells by interferon-7 and evaluation of the enzyme catalyzed tryptophan degradation in the anticellular activity. J. Biol. Chem., 263:2041-2048, 1988.
22. Ozaki, Y., Edelstein, M. P., and Duch, D. S. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon 7. Proc. Natl. Acad. Sci. USA, 85: 1242-1246, 1988.
23. de la Maza, L. M., and Peterson, E. M. Dependence of the in vitro antiproliferative activity of recombinant human 7-interferon on the concentration of tryptophan in culture media. Cancer Res., 48: 346-350,1988.
24. Knowles, R. G., Clarkson, N. A., Pogson, C. I., Salter, M., Duch, D. S., and Edelstein, M. P. The role of tryptophan and kynurenine transport in the catabolism of tryptophan through indoleamine 2,3-dioxygenase. In: R. Schwarcz, S. Young, and R. R. Brown (eds.), Kynurenine and Serotonin Pathways: Progress in Tryptophan Research, pp. 161-166. New York: Plenum Press, 1991.
25. Schiller, J. H., Storer, B., Pualnock, D. M., Brown, R. R., Datta, S. P., Witt, P. L., and Borden, E. C. A direct comparison of biological response modulation and clinical side effects of interferon-y-r, interferon-7, or the combination of interferons and 7 in humans. J. Clin. Invest., 86: 1211-1221, 1990.
26. Yoshida, R., Park, S. W., Yasui, H., and Takikawa, O. Tryptophan degradation in transplanted tumor cells undergoing rejection. J. Immunol., 141: 2819-2823, 1988.
27. Takikawa, O., Habara-Phkubo, A., and Yoshida, R. IFN-7 is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection. J. Immunol., 145: 1246-1250, 1990.